Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.66 |
| ▸ | GMPS | P49915 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4354580 | 0.91 | EGFR (0.78) | EGFRERBB2GMPS | |
| SCHEMBL18349206 | 0.89 | EGFR (0.57) | EGFRERBB2GMPS | |
| SCHEMBL18996626 | 0.88 | EGFR (0.64) | EGFRERBB2GMPSABCG2 | |
| SCHEMBL2100939 | 0.87 | EGFR (0.68) | EGFRERBB2GMPSHTTHIF1A | |
| SCHEMBL14286278 | 0.87 | EGFR (0.84) | EGFRERBB2GMPS | |
| SCHEMBL30865110 | 0.86 | GMPS (0.85) | EGFRGMPSHTTABCG2 | |
| SCHEMBL7802360 | 0.85 | EGFR (0.61) | EGFRERBB2GMPSHTTHIF1A | |
| Hydrochloric Acid SCHEMBL7807344 | 0.84 | EGFR (0.60) | EGFRERBB2GMPSHTTHIF1A | |
| SCHEMBL7809310 | 0.83 | EGFR (0.59) | EGFRERBB2GMPSHTTHIF1A | |
| SCHEMBL2994207 | 0.83 | EGFR (1.00) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174638-A1 | COMPOUNDS AND METHODS FOR INHIBITING VACUOLAR ATPASE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174638-A1 | COMPOUNDS AND METHODS FOR INHIBITING VACUOLAR ATPASE | NSF, ATP6V1H, ATP6V1G1 | EGFR 4294/4885ERBB2 3702/4885GMPS 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.